Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor
- PMID: 20541699
- DOI: 10.1016/j.ccr.2010.04.027
Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor
Abstract
Castration-recurrent prostate cancer (CRPC) is suspected to depend on androgen receptor (AR). The AF-1 region in the amino-terminal domain (NTD) of AR contains most, if not all, of the transcriptional activity. Here we identify EPI-001, a small molecule that blocked transactivation of the NTD and was specific for inhibition of AR without attenuating transcriptional activities of related steroid receptors. EPI-001 interacted with the AF-1 region, inhibited protein-protein interactions with AR, and reduced AR interaction with androgen-response elements on target genes. Importantly, EPI-001 blocked androgen-induced proliferation and caused cytoreduction of CRPC in xenografts dependent on AR for growth and survival without causing toxicity.
Copyright 2010 Elsevier Inc. All rights reserved.
Comment in
-
Grappling with the androgen receptor: a new approach for treating advanced prostate cancer.Cancer Cell. 2010 Jun 15;17(6):525-6. doi: 10.1016/j.ccr.2010.05.018. Cancer Cell. 2010. PMID: 20541694 Free PMC article.
-
Prostate cancer: A new tARget.Nat Rev Cancer. 2010 Aug;10(8):534-5. doi: 10.1038/nrc2897. Nat Rev Cancer. 2010. PMID: 20677355 No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
